Results 31 to 40 of about 3,628 (221)

Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock – a Case Series

Cellular Physiology and Biochemistry, 2017
Background/Aims: Patients with acute coronary syndromes (ACS) presenting with cardiogenic shock (CS) are at particular risk for death and adverse cardiac events.
Michal Droppa, Oliver Borst, Dominik Rath, Karin Müller, Meinrad Gawaz, Deepak L. Bhatt, Tobia Geisler   +6 more
doaj   +1 more source

Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization,secondary mediators, and Rac [PDF]

, 2010
The C-type lectin-like receptor 2 (CLEC-2)activates platelets through Src and Syk tyrosine kinases via a single cytoplasmic YxxL motif known as a hem immunoreceptor tyrosine-based activation motif (hemITAM).Here, we demonstrate using sucrose gradient ...
Alice Y. Pollitt, Atkinson, Barrow, Beata Grygielska, Bertrand Leblond, Bodin, Bodin, Boggon, Christou, Colonna, Eble, Ezumi, Fuller, He, Hooley, Hughes, Huysamen, Johannes A. Eble, Kerrigan, Laurent Désiré, Lee, Locke, May, McCarty, Pestina, Piechulek, Pierce, Pleines, Quek, Sancho, Schacht, Shutes, Simons, Sobanov, Spalton, Steve P. Watson, Suzuki-Inoue, Suzuki-Inoue, Tolias, Walliser, Watson, Watson, Wonerow, Wonerow, Xu   +44 more
core   +1 more source

Comparison of myocardial reperfusion between intracoronary versus intravenous cangrelor administration in patients undergoing primary percutaneous coronary intervention

Cardiology Journal, 2023
BACKGROUND: Myocardial reperfusion is the main target of treatment in patients with ST-segment elevation myocardial infarction (STEMI). The intracoronary administration of cangrelor bolus could favor a higher local drug concentration, favoring an earlier
Iacopo Muraca, Matteo Pennesi, Alessio Mattesini, Angela Migliorini, Nazario Carrabba, Giacomo Virgili, Filippo Bruscoli, Pierluigi Demola, Riccardo Colombi, Giulia Pontecorboli, Niccolò Marchionni, Carlo Di Mario, Renato Valenti   +12 more
doaj   +1 more source

Ibrutinib inhibits platelet integrin αIIbβ3 outside-in signaling and thrombus stability but not adhesion to collagen [PDF]

, 2015
OBJECTIVE: Ibrutinib is an irreversible Bruton tyrosine kinase inhibitor approved for treatment of Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, and mantle cell lymphoma that increases the risk of bleeding among patients. Platelets from
Alexander P. Bye, Alexander R. Stainer, Amanda J. Unsworth, Jonathan M. Gibbins, Michael J. Fry, Oda A, Sakthivel Vaiyapuri   +6 more
core   +1 more source

Intravenous cangrelor use for neuroendovascular procedures: a two-center experience and updated systematic review

Frontiers in Neurology, 2023
BackgroundThe optimal antiplatelet therapy regimen for certain neuroendovascular procedures remains unclear. This study investigates the safety and feasibility of intravenous dose-adjusted cangrelor in patients undergoing acute neuroendovascular ...
Harsh Desai, Mohammed Maan Al-Salihi, Rami Z. Morsi, Omar R. Vayani, Sachin A. Kothari, Sonam Thind, Julián Carrión-Penagos, Archit Baskaran, Ammar Tarabichi, Veronica A. Bonderski, James E. Siegler, Mary Hahn, Elisheva R. Coleman, James R. Brorson, Scott J. Mendelson, Ali Mansour, Guilherme Dabus, Michael Hurley, Shyam Prabhakaran, Italo Linfante, Tareq Kass-Hout   +20 more
doaj   +1 more source

A hopeful therapy for Niemann-Pick C diseases [PDF]

, 2017
Not abstract ...
Erickson, Robert P., Fiorenza, Maria Teresa   +1 more
core   +1 more source

Abstract Number ‐ 98: Intravenous dose‐adjusted cangrelor use for neuroendovascular procedures: An institutional experience

Stroke: Vascular and Interventional Neurology, 2023
Introduction The optimal antiplatelet therapy regimen for certain neuroendovascular procedures remains unclear. This study investigates the safety and feasibility of intravenous dose‐adjusted cangrelor in patients undergoing neuroendovascular procedures.
Rami Z. Morsi, Harsh Desai, Sachin Kothari, Sonam Thind, Julián Carrión‐Penagos, Elisheva Coleman, James R Brorson, Scott J Mendelson, Ali Mansour, Shyam Prabhakaran, Tareq Kass‐Hout   +10 more
doaj   +1 more source

Synthesis and Impurity Research of 2-Thioadenosine Monohydrate

Pharmaceutical Fronts, 2023
2-Thioadenosine monohydrate (1) is a vital intermediate in the synthesis of cangrelor. However, its industrial-scale preparation process and the analysis of the impurities formed during this process remained largely unknown.
Jing-Jing Xiang, Bi-Bo Jiang, Wen-Qing Sun, Fu-Li Zhang, Jun Yu   +4 more
doaj   +1 more source

Hobson’s choice; platelet inhibition and thrombocytopenia [PDF]

, 2018
No ...
Curzen, N, Mamas, MA
core   +1 more source

Newer agents in antiplatelet therapy: a review. [PDF]

, 2012
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core   +3 more sources